CAMBRIDGE, Mass., March 30 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. today announced three leadership promotions effective immediately: Julian Adams, Ph.D., to President and Chief Scientific Officer; Adelene Q. Perkins, to Executive Vice President and Chief Business Officer; and David S. Grayzel, M.D., to Vice President, Clinical Development and Medical Affairs. Steven H. Holtzman will continue to serve as Infinity's Chief Executive Officer and Chairman. These promotions reflect Infinity's commitment to leadership development and facilitate the advancement of Infinity's cancer drug discovery and development efforts to bring important new treatments to patients worldwide.
"I wish to congratulate Julian, Adelene, and David, who have played vital roles in the development of Infinity," said Steven Holtzman, Chief Executive Officer, Infinity. "Being a pioneer in the discovery and development of novel cancer therapeutics requires strong leaders. These promotions reflect the depth of the Infinity's management team and ensure we will remain a leader in cancer drug discovery and development well into the future."
Dr. Adams joined Infinity as Chief Scientific Officer in October 2003. Dr. Adams brought with him a track record of successfully discovering and developing several first-in-class agents including, most recently, Velcade(R), a proteasome inhibitor for cancer therapy and before that, Viramune(R) for the treatment of HIV. Dr. Adams received his Ph.D. from the Massachusetts Institute of Technology in the field of synthetic organic chemistry. He has received many awards, including the 2001 Ribbon of Hope Award for Velcade(R) from the International Myeloma Foundation. Dr. Adams is an inventor of over 40 patents and has authored over 100 papers and book chapters in peer-reviewed journals. In his new role as President and CSO, Dr. Adams continues to be responsible for the development of Infinity's world-class pharmaceutical R&D organization and the delivery of Infinity's strong pipeline of potentially important new medicines. In addition, Dr. Adams is taking on additional responsibility for the operation and shaping of the overall culture of Infinity.
Ms. Perkins has played an instrumental role in building Infinity since joining the Company in 2002 as Chief Business Officer. Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she served as Vice President of Business and Corporate Development. Prior to TransForm, Ms. Perkins was at Genetics Institute, now a unit of Wyeth, as Vice President of Emerging Businesses where she co-founded and ran DiscoverEase, a secreted protein focused business unit. She also formed and served as CEO of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University. Ms. Perkins holds an M.B.A. from Harvard Business School and a B.S. in Chemical Engineering from Villanova University. In her new role, as EVP and CBO, Ms. Perkins is responsible for Business Development, Corporate Strategy and Development, Finance, Organizational Development and Human Resources, IR/PR, Legal, and Facilities and Operations.
Since joining Infinity in 2002, Dr. Grayzel has made numerous contributions to both the science and business of the Company most recently in his position as Senior Director, Clinical Development and Medical Affairs. Dr. Grayzel joined Infinity from Dyax Corp, a biopharmaceutical company focused on antibody and protein therapeutics where he was Director of Corporate Development. Dr. Grayzel completed his internship and residency training in Internal Medicine at Massachusetts General Hospital after obtaining his medical degree at Harvard Medical School. Prior to his medical training, Dr. Grayzel was a Curriculum Director at Stanford University Medical Center. He holds a B.A. with honors from Stanford University. As Vice President of Clinical Development and Medical Affairs, Dr. Grayzel is responsible for expanding Infinity's translational research capability and continuing to build the Company's clinical organization and infrastructure.
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative cancer drug discovery and development company that leverages its strength in small molecule technologies to bring important new medicines to patients.
Editor's Note: This release is available in the Media Room section of the Infinity website at http://www.ipi.com.
Contacts: Adelene Q. Perkins Paul Kidwell (media) Executive Vice President, Kidwell Public Relations Chief Business Officer 617-296-3854 Infinity Pharmaceuticals, Inc. paul_kidwell@comcast.net 617-453-1104 Adelene.Perkins@ipi.com
Infinity Pharmaceuticals, Inc.CONTACT: Adelene Q. Perkins, Executive Vice President, Chief BusinessOfficer of Infinity Pharmaceuticals, Inc., +1-617-453-1104,Adelene.Perkins@ipi.com; or Paul Kidwell of Kidwell Public Relations,+1-617-296-3854, paul_kidwell@comcast.net
Web site: http://www.ipi.com//
